Advertisement

Neurological Sciences

, Volume 32, Supplement 1, pp 71–76 | Cite as

Disability in chronic daily headache: state of the art and future directions

  • Domenico D’AmicoEmail author
  • L. Grazzi
  • S. Usai
  • A. Raggi
  • M. Leonardi
  • G. Bussone
Symposium - Chronic Pain and Headache: New Legislation

Abstract

Aim of this literature review is to summarize the most relevant research findings on disability in subjects with chronic daily headache (CDH) and chronic migraine (CM) measured with the MIDAS and the HIT-6, and to address issues for further research in the field. Research strategy aimed to find papers published after 2001 that focused on disability in patients with CDH, CM and transformed migraine. Both, general population surveys or clinical series were included if they reported total scores, or distribution of the different disability levels, derived from the MIDAS and/or from the HIT-6. Fifteen papers were selected. Studies demonstrated that these subjects report a remarkable impact on functioning, with high disability scores, and reduced ability in work and non-work activities. Modern definitions of disability conceptualize it as the result of the interaction between a health condition and environmental factors. Research strategies should therefore recognize that disability may represent a global evaluation which should be added to more specific endpoints, using instruments that measure disability in a multi-dimensional way, such as the WHO-DAS II.

Keywords

Chronic daily headache (CDH) Chronic migraine Medication overuse (MO) MIDAS HIT-6 WHO-DAS II 

Notes

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

References

  1. 1.
    Sheftell FD, Tepper SJ (2002) New paradigms in the recognition and acute treatment of migraine. Headache 42:58–69PubMedCrossRefGoogle Scholar
  2. 2.
    D’Amico D, Moschiano F, Usai S, Bussone G (2006) Treatment strategies in the acute therapy of migraine: stratified care and early intervention. Neurol Sci 27:S117–S122PubMedCrossRefGoogle Scholar
  3. 3.
    D’Amico D, Solari A, Usai S, Progetto Cefalee Lombardia Group et al (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691–696PubMedCrossRefGoogle Scholar
  4. 4.
    Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50–S58PubMedCrossRefGoogle Scholar
  5. 5.
    Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062PubMedCrossRefGoogle Scholar
  6. 6.
    Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L (2007) The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 5:56PubMedCrossRefGoogle Scholar
  7. 7.
    Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19:107–114PubMedCrossRefGoogle Scholar
  8. 8.
    Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41–52PubMedCrossRefGoogle Scholar
  9. 9.
    Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974PubMedCrossRefGoogle Scholar
  10. 10.
    Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population based case–control study from England. Cephalalgia 23:441–450PubMedCrossRefGoogle Scholar
  11. 11.
    Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D (2004) Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 25:S105–S107PubMedCrossRefGoogle Scholar
  12. 12.
    Leonardi M, Steiner T, Scher A, Lipton R (2005) The global burden of migraine: Measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain 6:429–440PubMedCrossRefGoogle Scholar
  13. 13.
    Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210PubMedCrossRefGoogle Scholar
  14. 14.
    Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1–96CrossRefGoogle Scholar
  15. 15.
    Headache Classification. Subcommittee of the International Headache Society (2004) The international classification of headache disorders. Cephalalgia 24:S1–S160Google Scholar
  16. 16.
    Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746Google Scholar
  17. 17.
    Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and near-daily headaches: field trial of revised HIS criteria. Neurology 47:871–875PubMedGoogle Scholar
  18. 18.
    Lanteri-Minet M, Auray JP, El HA, Dartigues JF, Duru G, Henry P, Lucas C, Pradalier A, Chazot G, Gaudin AF (2003) Prevalence and description of chronic daily headache in the general population in France. Pain 102:143–149PubMedCrossRefGoogle Scholar
  19. 19.
    Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD (2003) Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 43:336–342PubMedCrossRefGoogle Scholar
  20. 20.
    Meletiche DM, Lofland JH, Young WB (2001) Quality-of-life differences between patients with episodic and transformed migraine. Headache 41:573–578PubMedCrossRefGoogle Scholar
  21. 21.
    D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, Bussone G (2003) Quality of life and disability in primary chronic daily headaches. Neurol Sci 24:S97–S100PubMedCrossRefGoogle Scholar
  22. 22.
    D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G (2005) Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache 45:553–560PubMedCrossRefGoogle Scholar
  23. 23.
    Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566PubMedCrossRefGoogle Scholar
  24. 24.
    Cassidy EM, Tomkins E, Hardiman O, O’Keane V (2003) Factors associated with burden of primary headache in a specialty clinic. Headache 43:638–644PubMedCrossRefGoogle Scholar
  25. 25.
    Magnoux E, Freeman MA, Zlotnik G (2008) MIDAS and HIT-6 French translation: reliability and correlation between tests. Cephalalgia 28:26–34PubMedGoogle Scholar
  26. 26.
    Lanteri-Minet M, Chautard MH, Lucas C (2005) Chronic migraine and medication overuse: results of Framig 3, a French population-based survey carried out according to the 2004 IHS classification. Neurology Suppl. 2:A132Google Scholar
  27. 27.
    Grazzi L, Andrasik F, D’Amico D, Usai S, Kass S, Bussone G (2004) Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up. Headache 44:678–683PubMedCrossRefGoogle Scholar
  28. 28.
    Andrasik F, Grazzi L, Usai S, Kass S, Bussone G (2010) Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia 30:610–614PubMedGoogle Scholar
  29. 29.
    Mathew NT, Kailasam J, Meadors L (2002) Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42:796–803PubMedCrossRefGoogle Scholar
  30. 30.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823PubMedCrossRefGoogle Scholar
  31. 31.
    Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ (2010) Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 37:588–594PubMedGoogle Scholar
  32. 32.
    Usai S, Grazzi L, D’Amico D, Andrasik F, Bussone G (2008) Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurol Sci 29:S176–S178PubMedCrossRefGoogle Scholar
  33. 33.
    Castillo J, Munoz P, Guitera V, Pascual G (1999) Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 39:190–196PubMedCrossRefGoogle Scholar
  34. 34.
    Grazzi L, Andrasik F (2006) Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep 10:71–77PubMedCrossRefGoogle Scholar
  35. 35.
    Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428–432PubMedCrossRefGoogle Scholar
  36. 36.
    D’Amico D (2010) Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol Sci 31:S23–S28PubMedCrossRefGoogle Scholar
  37. 37.
    World Health Organization (2001) The International Classification of Functioning, Disability and Health-ICF. WHO, GenevaGoogle Scholar
  38. 38.
    Leonardi M, Bickenbach J, Ustun TB,Kostanjsek N. Chatterji S, MHADIE consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221Google Scholar
  39. 39.
    Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, Alonso J, Cieza A, Svetskova O, Burger H, Racca V, Francescutti C, Vieta E, Kostanjsek N, Raggi A, Leonardi M, Ferrer M, MHADIE consortium (2010) Validation of the World Health Organization Disability Assessment Schedule (WHODAS-2) in patients with chronic diseases. Health Qual Life Outcomes 8:51Google Scholar
  40. 40.
    Federici S, Meloni F, Mancini A, Lauriola M, Olivetti Belardinelli M (2009) World Health Organisation Disability Assessment Schedule II: Contribution to the Italian validation. Disabil Rehabil 31:553–556PubMedCrossRefGoogle Scholar
  41. 41.
    Leonardi M, Raggi A, Bussone G, D’Amico D (2010) Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache 50:1576–1586PubMedCrossRefGoogle Scholar
  42. 42.
    Raggi A, Leonardi M, Bussone G, D’Amico D (2011) Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life. Neurol Sci doi: 10.1007/s10072-010-0466-3

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Domenico D’Amico
    • 1
    Email author
  • L. Grazzi
    • 1
  • S. Usai
    • 1
  • A. Raggi
    • 2
  • M. Leonardi
    • 2
  • G. Bussone
    • 1
  1. 1.Headache Center, Neurological Institute “C. Besta” IRCCS FoundationMilanItaly
  2. 2.Neurology, Public Health and Disability Unit, Neurological Institute “C. Besta” IRCCS FoundationMilanItaly

Personalised recommendations